Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post by Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, adding:
“With improving systemic therapies, surgical-sparing strategies are emerging across oncology. In bladder, rectal, breast cancer, a future paradigm may emerge in which, in the presence of pCR, definitive surgery could be safely omitted. Not ready yet, but the direction is clear.”
Quoting Tom Powles’s post:
“A 240 pateint single arm trial exploring 9 cycles of EVP without planned surgery in MIBC. This will answer the key questions ‘What happens if we don’t do cystectomy in those with clinical complete response after initial EVP’.It assesses cCR rates and bladder intact EFS. It will clarify ‘EVP 1st ask questions later’.”
Other articles featuring Paolo Tarantino on OncoDaily.